Associated Press NEW YORK — French pharmaceutical company Sanofi-Aventis SA said Thursday it has suspended enrollment in studies of its antibiotic Ketek in children, amid reports the drug can cause liver failure in adults. The company denied the studies were halted because of safety concerns and said it was only trying to ensure the trials' design complied with FDA requirements. The Paris-based company said the Food and Drug Administration did not request the action. It also said the suspension was not linked to a published report which said an FDA official last month requested the trials be halted because Ketek...